Large-scale cardiovascular outcome trials with GLP-1 RAs—such as LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide)—have demonstrated significant HbA1c reductions and robust cardiorenal protection in high-risk T2DM populations [10,11,12,13,14,15]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.